Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

09. April 2026 17:11 ET | Quelle: Strata Critical Medical, Inc

Strata Critical Medical to Present at the 25th Annual Needham Virtual Healthcare Conference

NEW YORK, April 09, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, “Strata” or the “Company”), today announced that management will present at the 25th Annual Needham Virtual...
09. April 2026 16:25 ET | Quelle: eHealth Exchange

eHealth Exchange Demonstrates Real-World Patient Access Capability, Advancing CMS-Aligned Network Goals

VIENNA, Va., April 09, 2026 (GLOBE NEWSWIRE) -- eHealth Exchange™ today announced a major milestone toward becoming a CMS-Aligned Network with the successful enablement and live demonstration of...
09. April 2026 16:25 ET | Quelle: Emergent BioSolutions

Emergent BioSolutions Partners with British Columbia to Supply NARCAN® Nasal Spray for the Launch of the Expanded BC Take Home Naloxone Program

WINNIPEG, Manitoba, April 09, 2026 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions (NYSE: EBS) announced that it has partnered with the B.C. Provincial Health Services Authority (PHSA) to supply...
09. April 2026 16:21 ET | Quelle: Sobi, Inc.

Sobi reçoit l’autorisation par Santé Canada pour EMPAVELIMD (pegcétacoplan) dans le traitement de la GC3 et de la GNMP-CI primitive.

EMPAVELIMD (pegcétacoplan) est le premier traitement autorisé dans le traitement des patients adultes et pédiatriques de 12 ans et plus atteints de glomérulopathie à dépôts de C3 (GC3) ou de...
09. April 2026 16:21 ET | Quelle: Sobi, Inc.

Sobi Receives Health Canada Approval for EMPAVELI® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN

EMPAVELI® (pegcetacoplan) is the first approved treatment for C3G or primary IC-MPGN for patients 12 years and older in Canada Approval supported by Phase 3 52-week VALIANT study demonstrated reduced...
09. April 2026 16:05 ET | Quelle: Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting

WEST CHESTER, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of...
09. April 2026 15:36 ET | Quelle: ClinNEXUS, Inc.

ClinNEXUS to Participate as Featured Speaker in Suncoast Ventures Gateway Conference on Healthcare Innovation

LOS ANGELES, April 09, 2026 (GLOBE NEWSWIRE) -- ClinNEXUS, (or the “Company”) a data-driven healthcare company that’s redefining care coordination by uniting clinical, social, and behavioral support...
09. April 2026 14:53 ET | Quelle: Kildare Road Medical Centre

Medical Centre in Blacktown goes Bulk Billed

Sydney, NEW SOUTH WALES, April 09, 2026 (GLOBE NEWSWIRE) -- Kildare Road Medical Centre has reaffirmed its commitment to accessible, community-focused healthcare by continuing to participate in the...
09. April 2026 13:24 ET | Quelle: Loyola University New Orleans

Loyola University New Orleans College of Nursing and Health Awarded $2.85 Million to Expand Nursing Education and Training

New Orleans, April 09, 2026 (GLOBE NEWSWIRE) -- NEW ORLEANS, LA – Loyola University New Orleans was awarded $2.85 million in new federal funding to strengthen nursing education and prepare more...
09. April 2026 11:41 ET | Quelle: Joyce University of Nursing and Health Sciences

Joyce University Named a 2026 USA Today Top Workplace for Third Consecutive Year

SALT LAKE CITY, UT, April 09, 2026 (GLOBE NEWSWIRE) -- Joyce University of Nursing and Health Sciences has been named a 2026 USA Today Top Workplaces award winner, marking the third consecutive year...

Vorherige Seite

Nächste Seite